Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-HF
CTR20253469Phase 3Active
- Sponsor
- Amgen
- Start
- Oct 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of maridebart cafraglutide in heart failure (HF), obesity, sponsored by Amgen. Started Oct 2025; status: active.
02
Drugs
maridebart cafraglutide
03
Conditions
heart failure (HF)obesity
Beyond the preview
Go deeper on CTR20253469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253469.